Jefferies Group LLC Analysts Give Sanofi SA (SAN) a €86.00 Price Target
Sanofi SA (EPA:SAN) has been assigned a €86.00 ($102.38) target price by stock analysts at Jefferies Group LLC in a report issued on Monday. The firm currently has a “neutral” rating on the stock.
SAN has been the subject of several other research reports. Goldman Sachs Group, Inc. (The) set a €82.00 ($97.62) price target on shares of Sanofi SA and gave the company a “neutral” rating in a report on Tuesday, August 1st. S&P Global set a €90.00 ($107.14) price target on shares of Sanofi SA and gave the company a “neutral” rating in a report on Monday, July 31st. Berenberg Bank set a €97.00 ($115.48) price target on shares of Sanofi SA and gave the company a “neutral” rating in a report on Monday, July 31st. Sanford C. Bernstein set a €90.00 ($107.14) price target on shares of Sanofi SA and gave the company a “neutral” rating in a report on Monday, July 31st. Finally, Kepler Capital Markets set a €89.00 ($105.95) price target on shares of Sanofi SA and gave the company a “buy” rating in a report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the company. Sanofi SA currently has an average rating of “Hold” and a consensus price target of €87.81 ($104.54).
Sanofi SA (SAN) opened at 81.58 on Monday. The firm has a market cap of €102.44 billion and a price-to-earnings ratio of 11.38. The company has a 50-day moving average of €26.12 and a 200-day moving average of €25.99. Sanofi SA has a 1-year low of €24.55 and a 1-year high of €81.60.
About Sanofi SA
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Stock Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related stocks with our FREE daily email newsletter.